LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Barasertib | 10 | uM | LJP5 | 72 | hr | 1209 | 1468 | 4203 | 0.3504 | 0.1148 |
| MCF7 | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4065 | 4203 | 0.9658 | 0.9591 |
| MCF7 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4214 | 4203 | 1.0032 | 1.0027 |
| MCF7 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4347 | 4203 | 1.0360 | 1.0407 |
| MCF7 | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 4204 | 4203 | 1.0003 | 1.0002 |
| MCF7 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4259 | 4203 | 1.0147 | 1.0170 |
| MCF7 | Vemurafenib | 10 | uM | LJP5 | 72 | hr | 1209 | 3596 | 4203 | 0.8555 | 0.8330 |
| MCF7 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4044 | 4203 | 0.9622 | 0.9572 |
| MCF7 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4339 | 4203 | 1.0323 | 1.0357 |
| MCF7 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4092 | 4203 | 0.9728 | 0.9684 |
| MCF7 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1209 | 3959 | 4203 | 0.9436 | 0.9368 |
| MCF7 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3917 | 4203 | 0.9339 | 0.9262 |
| MCF7 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 1209 | 2911 | 4203 | 0.6935 | 0.6314 |
| MCF7 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2761 | 4012 | 0.6898 | 0.6137 |
| MCF7 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 1209 | 2372 | 4012 | 0.5925 | 0.4778 |
| MCF7 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 1209 | 2022 | 4012 | 0.5043 | 0.3460 |
| MCF7 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 1209 | 1989 | 4012 | 0.4963 | 0.3336 |
| MCF7 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1850 | 4012 | 0.4622 | 0.2794 |
| MCF7 | Palbociclib | 10 | uM | LJP6 | 72 | hr | 1209 | 1820 | 4012 | 0.4540 | 0.2665 |
| MCF7 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3497 | 4012 | 0.8741 | 0.8510 |
| MCF7 | PF562271 | 0.12 | uM | LJP6 | 72 | hr | 1209 | 3018 | 4012 | 0.7526 | 0.6969 |
| MCF7 | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 1209 | 2452 | 4012 | 0.6113 | 0.5042 |
| MCF7 | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 1209 | 1775 | 4012 | 0.4436 | 0.2494 |
| MCF7 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1125 | 4012 | 0.2812 | -0.0405 |
| MCF7 | PF562271 | 10 | uM | LJP6 | 72 | hr | 1209 | 701 | 4012 | 0.1746 | -0.2714 |